science wire

« BACK

Pharmacology



Results 1501 - 1550 of 1869.


Pharmacology - Health - 21.02.2014
Novartis shows continued commitment in Japan with Lucentis approval in fourth Japanese indication, diabetic macular edema
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.m. 5:00 p.m. EST More information Global Media Relations Eric Althoff Basel, Switzerland +41 61 324 7999 eric.althoff [a] novartis (p) com More information Investor Relations Switzerland investor.relations [a] novartis (p) com

Health - Pharmacology - 19.02.2014
Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 17.02.2014
Novartis expands cancer immunotherapy research program with acquisition of CoStim
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Economics / Business - Pharmacology - 29.01.2014
Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Economics / Business - 27.01.2014
Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 24.01.2014
Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 24.01.2014
Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 12.01.2014
Hervé Hoppenot, President of Novartis Oncology, leaves Novartis to pursue career opportunity outside of organization
Main switchboard Switzerland +41 61 324 11 11 +41 61 324 80 01 Monday - Friday, 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 Monday - Friday, 8:30 a.

Pharmacology - Health - 19.12.2013
Sandoz begins Phase III clinical trial for biosimilar adalimumab
Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio Global program marks Sandoz' sixth biosimilar molecule to enter Phase III testing Trial will support registration in

Health - Pharmacology - 18.12.2013
Sandoz receives first approval for AirFluSal Forspiro
Novel inhaler approved for patients with asthma and COPD Approval follows completion of EU decentralized procedure (DCP) AirFluSal Forspiro strengthens Sandoz respiratory portfolio and reinforces com

Pharmacology - Health - 09.12.2013
Novartis drug Jakavi improved overall survival of patients with myelofibrosis in four separate analyses of long-term Phase III studies
In two Phase III studies, Jakavi reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with and without high-risk mutations Separate analysis shows Jakavi may increase the probability of 10-year survival of myelofibrosis patients by more than 50% compared to conventional therapy Jakavi is the only JAK inhibitor approved in more than 50 coun

Pharmacology - Health - 09.12.2013
New five-year data support superiority of Novartis drug Tasigna over Glivec in newly diagnosed Ph+ CML patients
ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec Data demonstrated higher rates of early and deeper molecul

Health - Pharmacology - 07.12.2013
Novartis highlights research on investigational, personalized’T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia , , , Presentations include findings that 19 of 22 pediatric patients with acute lymphoblastic leukemia ( ALL) (86%) experienced complete remissions Novartis and Penn exclusive global collaboration to develop chimeric antigen receptor (CAR) technology is moving forward with the goal of expanding clinical

Pharmacology - Health - 06.12.2013
Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study
Study of LBH589 plus bortezomib and dexamethasone met primary endpoint of extending PFS compared to bortezomib plus dexamethasone and placebo LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma Data will be presented at an upcoming medical congress and discussed with regulatory authorities worldwide Basel, December 6, 2013 - Novartis today announced that results of a Phase III trial

Health - Pharmacology - 05.12.2013
Novartis Africa Day highlights company’s efforts to expand access to healthcare
Africa's healthcare challenges are compounded as it begins to face a dual disease burden as non-communicable diseases rise In addition to existing corporate responsibility efforts such as its Malaria

Pharmacology - Health - 04.12.2013
Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
Multiple studies evaluating deep molecular response with Tasigna versus Glivec in Ph+ CML patients Overall survival data from Jakavi Phase III trials in patients with the debilitating blood cancer, m

Pharmacology - Life Sciences - 04.12.2013
Tuberculosis: Nature has a double-duty antibiotic up her sleeve
Tuberculosis: Nature has a double-duty antibiotic up her sleeve
A natural antibiotic turns out to be a lethal weapon in the fight against tuberculosis. Scientists have discovered it has an unexpected dual action that dramatically reduces the probability that TB bacteria will become resistant. Technology has made it possible to synthesize increasingly targeted drugs.

Pharmacology - Economics / Business - 22.11.2013
Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
Novartis takes action to strengthen portfolio and capital allocation, starts share buyback Blood transfusion diagnostics unit divested as part of ongoing portfolio management Reiterates optimal capit

Life Sciences - Pharmacology - 17.11.2013
How botox binds to neurons
How botox binds to neurons
Media Releases Biology Research Using Synchrotron Light Human Health Researchers elucidate how botulinum neurotoxin A binds to its protein receptor and thus provide a basis for the development of new drugs Botulinum neurotoxin A, better known as botox, is a highly dangerous toxin that causes paralysis in man that may prove fatal.

Pharmacology - Innovation - 14.11.2013
Novartis announces positive clinical trial results for novel H7N9 vaccine
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59 adjuvant Vaccine now in large scale production highlightin

Health - Pharmacology - 23.10.2013
Alcon receives positive NICE recommendation for Jetrea to treat eligible patients with vitreomacular traction, including macular hole
One-time single eye injection of Jetrea recognized as clinically and cost-effective treatment for eligible patients with vitreomacular traction, including macular hole Jetrea is the first and only ap

Economics / Business - Pharmacology - 22.10.2013
Novartis delivers strong sales performance in third quarter driven by growth products’ momentum; innovation newsflow reinforces growth prospects
Group net sales up 4% (+6% cc ) to USD 14.3 billion in third quarter and up 2% (+4% cc) in first nine months; all divisions contributed to growth Negative currency impact of 6 percentage points

Pharmacology - Health - 05.10.2013
Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU
Omalizumab significantly reduced itch and hives caused by chronic spontaneous urticaria (CSU) as early as Week 1; benefit sustained over 24 weeks of active treatment Omalizumab 300 mg was nearly twice as effective in improving patients' quality of life within 12 weeks of treatment versus placebo ASTERIA I is the final omalizumab CSU registration study to be presented; regulatory applications were filed with EU and US authorities in Q3 2013 CSU i

Health - Pharmacology - 04.10.2013
New data show Novartis’ Gilenya reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients
New four-year data showed that continued Gilenya treatment reduced brain volume loss by one third when compared to delaying Gilenya by two years. MS patients with higher rates of brain volume loss were more likely to experience disease progression. Patients who remained free of disease had consistently lower rates of brain volume loss compared to patients who experienced disease activity.

Pharmacology - Health - 03.10.2013
Secukinumab showed superiority over Enbrel in clearing skin
Secukinumab (AIN457) patients' skin cleared faster and for longer than Enbrel (etanercept) patients, beginning as early as Week 2 Study also showed twice as many secukinumab patients experienced clear or almost clear skin by Week 12 versus Enbrel Head-to-head study of secukinumab and Enbrel part of largest clinical program completed in moderate-to-severe plaque psoriasis with more than 3,300 patients Secukinumab is the first IL-17A inhibitor wit

Pharmacology - Health - 03.10.2013
Real-world evidence showed superiority of Novartis’ Gilenya to reduce MS relapse rates compared to interferons or glatiramer acetate
Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual's level of disability Recovering from a relapse can take weeks or months for a patient with MS, and approximately half of all relapses may leave lasting

Health - Pharmacology - 01.10.2013
FDA grants Roche’s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer
FDA grants Roche's Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer The Perjeta regimen is the first treatment approved under a new FDA pathw

Pharmacology - Health - 30.09.2013
Novartis to reveal landmark Phase III results from specialty dermatology portfolio at upcoming EADV 2013 congress
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel * (etanercept) in moderate-to-severe plaque psoriasis to be revealed Results from three additional secukinumab Phase III studies also to be presented for the first time Secukinumab is the first IL-17A inhibitor with Phase III data and is on track to be the first psoriasis medication filed targeting IL-17A New data to be reported from final omalizumab registra

Pharmacology - Health - 27.09.2013
New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications
Pivotal myopic CNV trials with Lucentis (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year New data suggest early treatment initiation with Lucentis results in better vision gains in DME patients Meta-analysis of 14 trials and 6504 patients confirms well-established Lucentis safety profile reported from real-world experience and extensive clinical trials Basel, September 27, 2013 - New c

Pharmacology - Life Sciences - 25.09.2013
Data at ECTRIMS to confirm Novartis’ Gilenya long-term efficacy on reducing brain volume loss and real-world relapse rates in MS
New four-year data will show continued Gilenya treatment reduced brain volume loss in MS patients compared to delaying treatment with Gilenya by two years Data will strengthen the link between brain volume loss and disability progression, highlighting the importance of reducing brain volume loss in patients with MS Real-world patient data will confirm superiority of Gilenya compared to standard therapies (interferon and glatiramer acetate) in re

Pharmacology - Health - 23.09.2013
Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan
Ultibro Breezhaler (QVA149) is the first once-daily dual bronchodilator to gain European Commission approval as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD In Japan, once-daily Ultibro Inhalation Capsules (QVA149), delivered through the Breezhaler device, approved for relief of various symptoms due to airway obstruction in COPD Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including breathlessness and rescue medication use, compared to current standards of care - .

Pharmacology - Health - 23.09.2013
Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths
Power of One enables the public to fund malaria tests and treatments for children in Africa through the latest online and mobile technology Novartis is the exclusive campaign treatment sponsor and wi

Pharmacology - Health - 19.09.2013
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
CML community recognizes September 22 as World CML Day to raise awareness of the needs of patients living with CML Novartis commemorates World CML Day, announcing 100+ study sites across 40 countries now enrolling patients to its global treatment-free remission clinical trials Treatment-free remission program evaluates whether patients can maintain undetectable levels of disease after stopping nilotinib therapy Basel, September 19, 2013 - Novart

Health - Pharmacology - 08.09.2013
Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro Breezhaler (QVA149)
New analyses in the IGNITE clinical trial program showed that QVA149 provided superior, rapid and sustained improvements in lung function and significantly reduced shortness of breath versus comparator therapies , BLAZE study also demonstrated significant improvements in shortness of breath with QVA149 compared to tiotropium 18 mcg in patients with moderate-to-severe COPD SPARK study showed similar rates of reduction in exacerbations with once-d

Pharmacology - Health - 06.09.2013
Novartis announces an exclusive global licensing and research collaboration with Regenerex, leveraging a novel cell platform to broaden presence in the cell therapy space
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need Strategic research collaboration enlarges scop

Pharmacology - Health - 04.09.2013
Novartis marks 30 year anniversary in transplantation and reinforces continued commitment to organ recipients at ESOT congress
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin TRANSFORM trial to be presented : largest ever study of its kind, evaluating Certica

Health - Pharmacology - 04.09.2013
Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013
Robust efficacy of once-daily Ultibro Breezhaler (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro LABA+LAMA combination for the treatment of COPD patients , , Once-daily Seebri Breezhaler (glycopyrronium) efficacy data strengthened by new analyses from the SPARK study on exacerbations and lung function in severe and very severe COPD patients , Basel, September 4,

Pharmacology - Health - 03.09.2013
Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given

Health - Pharmacology - 02.09.2013
Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2]
New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress , If approved, RLX030 has the potential to be the first treatment breakthrough for AHF patients in 20 years , Basel, September 2, 2013 - Results from a new analysis of the Phase III RELAX-AHF study published today in the European Heart Journal and presented as a late breaker at the European Society of C

Pharmacology - Health - 20.08.2013
Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)
BYM338 is the third Novartis investigational treatment this year to receive a breakthrough therapy designation by the FDA, highlighting Novartis' leadership in the industry in breakthrough therapy designations Basel, August 20, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM).

Health - Pharmacology - 15.08.2013
Novartis vaccine Bexsero approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis
Australia approval marks a key step in expanding access to the first and only broad coverage vaccine against MenB disease , ; Bexsero was granted European licensure this past January MenB disease is

Health - Pharmacology - 08.08.2013
Novartis first company accredited with global "CEO Cancer Gold Standard" for outstanding efforts in cancer prevention and treatment
The non-profit CEO Roundtable on Cancer has recognized the programs Novartis has to support associates in the prevention, diagnosis and treatment of cancer Originally recognized for these efforts in

Health - Pharmacology - 07.08.2013
Study of Afinitor in advanced liver cancer does not meet primary endpoint of overall survival
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib Study results do not impact use of Afinitor in othe

Health - Pharmacology - 01.08.2013
FDA expands age indication for Menveo , first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]
Meningococcal disease is a leading cause of bacterial meningitis, a rapidly progressing disease that can lead to death in otherwise healthy children , The highest rates of meningococcal disease in th

Health - Pharmacology - 26.07.2013
Novartis receives positive CHMP opinion for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
The CHMP has endorsed the use of Ilaris in patients aged 2 years and older who suffer from Systemic Juvenile Idiopathic Arthritis (SJIA) In Phase III studies, 84% of Ilaris-treated SJIA patients achi

Health - Pharmacology - 26.07.2013
Novartis first in class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) gains positive CHMP opinion for the treatment of COPD
QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of both a LABA and a LAMA bronchodilator to gain positive CHMP opinion Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including breathlessness and rescue medication use, compared to current standard of care QVA149 demonstrated significantly reduced rates of COPD exacerbations and improved health-relat

Health - Pharmacology - 24.07.2013
UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease, following JCVI interim recommendation on Novartis Bexsero vaccine
JCVI takes interim position to not recommend Bexsero for the routine immunization program, driven by evaluation based on cost-effectiveness assumptions The evaluation by JCVI was made prior to any pr

Pharmacology - Chemistry - 24.07.2013
A new method for clicking molecules together
A new method for clicking molecules together
Scientists at EPFL have developed a quick and simple method for connecting and assembling new molecules together, paving a new road for synthetic chemistry, material science, chemical biology, and even drug discovery. Thiols are sulfur-containing molecules found in most proteins of the human body. Characterized by their 'garlicky' smell, they also give coffee, sweat and the spray of skunks their unique odor.

This site uses cookies and analysis tools to improve the usability of the site. More information. |